5-Amino-1MQ
★ 705-Amino-1-methylquinolinium
NNMT inhibitor for fat loss without appetite suppression
Fat LossAbout
5-Amino-1MQ is a synthetic small molecule (not a true peptide) that selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that depletes the methyl donors and NAD+ precursors used for cellular energy production. Blocking NNMT in adipocytes shifts fat cells from storage to fuel-burning mode and raises intracellular NAD+ and S-adenosyl-methionine. Unlike GLP-1 drugs, it produces fat-mass reduction in rodents without suppressing appetite or food intake. All current dosing comes from mouse studies scaled to human equivalents — no published Phase 1 human trial exists.
Mechanism
Selectively inhibits NNMT in adipose and liver tissue, preserving nicotinamide for NAD+ synthesis and raising SAM cofactor pools, which promotes fatty-acid oxidation and reduces adipocyte size.
Dosage
beginner
- Amount
- 50 mg
- Frequency
- 1x per day (morning)
- Route
- Oral capsule
- Duration
- 2 weeks (titration)
standard
- Amount
- 100 mg
- Frequency
- 1x per day (morning)
- Route
- Oral capsule
- Duration
- 8-12 weeks
advanced
- Amount
- 150 mg or 50 mg 2x/day
- Frequency
- 1-2x per day
- Route
- Oral capsule
- Duration
- 8-12 weeks
Morning only. Afternoon or evening dosing commonly causes insomnia due to elevated NAD+ and mild stimulant-like effects.
8-12 week cycles followed by 4-6 weeks off to allow baseline NNMT activity to reset.
Reconstitution & Storage
Oral compound — no reconstitution needed.
Capsules: room temperature, sealed, stable ~12 months. Avoid heat and moisture.
Benefits
- • Fat-mass reduction without appetite suppression
- • Raises intracellular NAD+ and SAM cofactor pools
- • Improves liver metabolic markers in obese mice
- • Preserves lean mass (no muscle loss in rodent studies)
- • Does not reduce food intake — useful when appetite suppression is undesirable
Side effects
- • Mild warmth and slightly elevated resting heart rate (weeks 1-2)
- • Insomnia if dosed afternoon or evening
- • Mild digestive upset with oral capsules
- • Reduced exercise tolerance during early cardiovascular training
- • Theoretical liver enzyme changes (baseline and post-cycle ALT/AST recommended)
Contraindications
- • Pregnancy and breastfeeding
- • Active cancer or recent cancer history (NNMT role in tumor biology unclear)
- • Liver disease
- • Children and teenagers
- • Known sleep disorders
- • Concurrent methotrexate, methylated B vitamins, or methyl-donor-sensitive psychiatric drugs
Gender notes
Men
Standard dosing applies. Popular in body recomposition stacks targeting visceral fat.
Women
Standard dosing applies. No estrogen interaction reported, but no human trials have included women specifically.
Research
- Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat diet-induced obesity in mice ↗
First demonstration that 5-Amino-1MQ inhibits NNMT, raises NAD+ in adipocytes, and reduces white-adipose mass and body weight in diet-induced obese mice without changing food intake.
Biochemical Pharmacology · 2018
- Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity ↗
Foundational proof-of-concept showing genetic knockdown of NNMT in adipose tissue protects mice from diet-induced obesity, validating NNMT as a metabolic target.
Nature · 2014
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice ↗
Combining 5-Amino-1MQ with a reduced-calorie diet produced synergistic reductions in fat and liver-fat mass beyond either intervention alone.
Scientific Reports · 2022
Stacks well with
Track 5-Amino-1MQ doses in the app
Built-in reconstitution calculator, dose log, and reminders. Free on Android.
Get on Google PlayEducational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.